ストックスクリーナーアプリを入手
11.21
6.39%
-0.765
アフターアワーズ：
11.40
0.185
+1.65%
前日終値:
$11.98
開ける：
$11.8
24時間の取引高:
1.72M
Relative Volume:
1.98
時価総額：
$1.45B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-12.59%
1か月 パフォーマンス:
-36.82%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$11.10
$12.32
1週間の範囲:
$11.10
$13.22
52週間の値動き範囲:
$11.10
$28.23
Kailera Therapeutics Inc Stock (KLRA) Company Profile
Compare KLRA vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRA
Kailera Therapeutics Inc
|
11.21 | 1.45B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kailera Therapeutics Inc Stock (KLRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-05-12 | 開始されました | Evercore ISI | Outperform |
| 2026-05-12 | 開始されました | JP Morgan | Overweight |
| 2026-05-12 | 開始されました | Jefferies | Buy |
| 2026-05-12 | 開始されました | Leerink Partners | Outperform |
| 2026-05-12 | 開始されました | TD Cowen | Buy |
| 2026-05-12 | 開始されました | William Blair | Outperform |
すべてを表示
Kailera Therapeutics Inc (KLRA) 最新ニュース
868,160 Shares of Kailera Therapeutics, Inc. $KLRA Acquired by State Street Corp - MarketBeat
Top Kailera Therapeutics (KLRA) Competitors 2026 - MarketBeat
KLRA: Differentiated GLP-1 assets and strategy position the company for growth in the expanding obesity market - TradingView
Kailera at bernstein healthcare forum: betting on obesity differentiation By Investing.com - Investing.com Canada
Kailera at bernstein healthcare forum: betting on obesity differentiation - Investing.com
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month LowWhat's Next? - MarketBeat
Weight-loss drug developers line up to tap lucrative market as competition heats up - Reuters
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 5.5%Time to Sell? - MarketBeat
Kailera Therapeutics, Inc.(NasdaqGS:KLRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Kailera Therapeutics, Inc.(NasdaqGS: KLRA) added to S&P Global BMI Index - marketscreener.com
Kailera Therapeutics: Hold Due To Need For Progress On Weight Loss Differentiation (KLRA) - Seeking Alpha
Kailera Therapeutics targets obesity with GLP-1 drug, raising $718M in IPO despite 40% share drop. - Pluang
Kailera Therapeutics: An Outside Biotech Bet For The Next GLP-1 Obesity Drug Approval - Seeking Alpha
Kailera Therapeutics to Participate in September Investor Conferences - The Manila Times
Kailera Therapeutics to Participate in Upcoming Investor Conferences - Quiver Quantitative
Kailera Therapeutics (NASDAQ:KLRA) Hits New 52-Week LowTime to Sell? - MarketBeat
Four executives will appear in Kailera's September webcasts - Stock Titan
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth” - finance.yahoo.com
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Sets New 52-Week LowWhat's Next? - MarketBeat
Kailera Therapeutics (KLRA) grants CTO 220,000 stock options - Stock Titan
Kailera Therapeutics (KLRA) CTO reports no shares in first ownership filing - Stock Titan
Kailera Therapeutics (NASDAQ:KLRA) Shares Down 7%Should You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Frazier Life Sciences Management L.P. Acquires Shares of 1,100,000 Kailera Therapeutics, Inc. $KLRA - MarketBeat
Atlas Venture Life Science Advisors LLC Makes New Investment in Kailera Therapeutics, Inc. $KLRA - MarketBeat
2,919,110 Shares in Kailera Therapeutics, Inc. $KLRA Acquired by Wellington Management Group LLP - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading Up 7.9%Here's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Kailera Stock Falls 12.5%, Leaving Market Value Just $930 Million Above Cash - ts2.tech
Kailera Therapeutics (NASDAQ:KLRA) Trading Down 8.6%Should You Sell? - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Trading 8.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (NASDAQ:KLRA) Hits New 1-Year LowHere's Why - MarketBeat
2 GLP-1 Stocks That Could Double Your Money by 2031 - AOL.com
KLRA Price Today: Kailera Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Kailera Therapeutics, Inc. (NASDAQ:KLRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Hengrui Pharma's Innovative Drug Revenue Share Tops 60% in H1; Two NewCo Partners List on Nasdaq - finance.biggo.com
KLRA Archives - 24/7 Wall St.
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More - AOL.com
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore - 24/7 Wall St.
Kailera Therapeutics (NASDAQ:KLRA) Trading 6.6% HigherHere's Why - MarketBeat
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified? - Yahoo Finance
Canada Pension Plan (KLRA) discloses 5.6% Kailera Therapeutics ownership in 13G filing - Stock Titan
Jefferies Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G - Stock Titan
J.P. Morgan Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $30 - Moomoo
TD Cowen Maintains Kailera Therapeutics(KLRA.US) With Buy Rating, Maintains Target Price $57 - Moomoo
KLRA SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
William Blair Maintains Kailera Therapeutics(KLRA.US) With Buy Rating - Moomoo
KAILERA THERAPEUTICS ($KLRA) Releases Q2 2026 Earnings - Quiver Quantitative
Kailera Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kailera Therapeutics Inc (KLRA) 財務データ
Kailera Therapeutics Inc (KLRA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):